SCHEMBL802691

SCHEMBL802691

Cc1ccccc1-c1nc(Nc2n[nH]c3ccccc23)nc(C2CCCCC2)n1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GSK3A P49840 2/20 0.46
GSK3B P49841 2/20 0.46
S1PR1 P21453 1/20 0.40
S1PR5 Q9H228 1/20 0.40
CYP1A2 P05177 4/20 0.39
CYP3A4 P08684 3/20 0.39
CLK4 Q9HAZ1 3/20 0.39
ALDH1A1 P00352 3/20 0.39
CYP2D6 P10635 2/20 0.39
TSHR P16473 1/20 0.39
MAPK1 P28482 1/20 0.39
PDE5A O76074 2/20 0.39
HSD17B10 Q99714 3/20 0.39
ADRA2A P08913 2/20 0.37
TRPA1 O75762 1/20 0.36
ALOX15 P16050 2/20 0.36
USP2 O75604 1/20 0.36
CYP2C19 P33261 1/20 0.36
FADS1 O60427 2/20 0.34
LMNA P02545 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL802369 0.89 GSK3A (0.63) GSK3AGSK3BS1PR1S1PR5CYP1A2
SCHEMBL802704 0.88 GSK3A (0.42) GSK3AGSK3BCYP1A2CYP3A4CLK4
SCHEMBL805543 0.85 USP1 (0.49) GSK3AGSK3BCYP1A2CYP3A4CLK4
SCHEMBL802094 0.82 PIK3CA (0.45) CYP1A2CYP3A4CLK4ALDH1A1CYP2D6
SCHEMBL802710 0.82 GSK3A (0.42) GSK3AGSK3BS1PR1S1PR5ALDH1A1
SCHEMBL13925120 0.78 GSK3B (0.38) GSK3AGSK3BPDE5AADRA2ATRPA1
SCHEMBL801704 0.77 PIK3CA (0.40) CYP1A2CYP3A4CLK4ALDH1A1CYP2D6
SCHEMBL801696 0.77 GSK3A (0.58) GSK3AGSK3BPDE5AFADS1EGFR
SCHEMBL801677 0.77 ALDH1A1 (0.46) GSK3AGSK3BCYP1A2CYP3A4CLK4
SCHEMBL805596 0.76 GSK3A (0.56) GSK3AGSK3BCYP1A2CYP3A4CLK4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8633210-B2 Triazole compounds useful as protein kinase inhibitors VERTEX PHARMACEUTICALS INCORPORATED (US) 2014-01-21 US disclosed
US-20120071657-A1 TRIAZOLE COMPOUNDS USEFUL AS PROTEIN KINASE INHIBITORS VERTEX PHARMACEUTICALS INCORPORATED (US) 2012-03-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120071657-A1 TRIAZOLE COMPOUNDS USEFUL AS PROTEIN KINASE INHIBITORS GSK3B, GSK3A, CDK19 GSK3A 2/4885GSK3B 1/4885S1PR1 2655/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.